Review, 2024

Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment

Applied Biochemistry and Biotechnology, ISSN 0273-2289, 1559-0291, Volume 196, 3, Pages 1685-1711, 10.1007/s12010-023-04597-5

Contributors

Tabasi H. [1] Mollazadeh S. [2] Fazeli E. [3] Abnus K. [1] Taghdisi S.M. Ramezani M. (Corresponding author) [1] Alibolandi M. (Corresponding author) [1]

Affiliations

  1. [1] Mashhad University of Medical Sciences
    2. [NORA names: Iran; Asia, Middle East];
  2. [2] North Khorasan University of Medical Sciences
    3. [NORA names: Iran; Asia, Middle East];
  3. [3] Aarhus University
    4. [NORA names: AU Aarhus University; University; Denmark; Europe, EU; Nordic; OECD]

Abstract

Conventional cancer therapies with chemodrugs suffer from various disadvantages, such as irreversible side effects on the skin, heart, liver, and nerves with even fatal consequences. RNA-based therapeutic is a novel technology which offers great potential as non-toxic, non-infectious, and well-tolerable platform. Herein, we introduce different RNA-based platforms with a special focus on siRNA, miRNA, and mRNA applications in cancer treatment in order to better understand the details of their therapeutic effects. Of note, the co-delivery of RNAs with other distinct RNA or drugs has provided safe, efficient, and novel treatment modalities for cancer treatment. Graphical Abstract: (Figure presented.)

Keywords

Cancer-therapy, Immunotherapy, Oligonucleotide, mRNA, miRNA, siRNA

Funders

  • Mashhad University of Medical Sciences

Data Provider: Elsevier

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+